We are conducting world first research in the use of artificial intelligence for epilepsy treatment.
Researchers at Monash University are seeking adults (18 years or older) diagnosed with epilepsy and neurologists/epileptologists to participate in the uniquely collaborative study.
For people newly diagnosed with epilepsy, the effectiveness of the first antiseizure medication is very important. New technologies are emerging, such as machine learning, that could assist clinicians to make more personalised and effective medication decisions that achieve seizure control after diagnosis faster than traditional methods. However, securing the downstream benefits from such tools is critically dependent on how the outputs of the model are implemented by
physicians and received by patients.
Our team has developed a world-first machine learning (ML)-based clinical decision support (CDS) tool in antiseizure medication selection. To better understand people’s thoughts about such technology in health care, we are conducting interviews with people with epilepsy and neurologists/epileptologists to explore their attitudes, values, beliefs, goals, concerns, and perceptions about machine learning input into clinician decision making with respect to the prescription of first antiseizure medication. Meaningful engagement with participants will help ensure our research provides the best possible outcomes for the epilepsy community.
Participation in the research will involve completing a semi-structured interview on Zoom or the telephone. we would like to hear your thoughts about machine learning input into clinician decision making regarding choice of antiseizure medication for adolescents/adults with newly diagnosed epilepsy.
For more information please complete the from below or contact the project manager Dr. Mark Howard at email
mark.howard@monash.edu